Wikipedia preview

出典(authority):フリー百科事典『ウィキペディア（Wikipedia）』「2012/03/03 15:09:47」(JST)

wiki en

Immunoscintigraphy is a procedure used to find cancer cells in the body by injecting a radioactively labeled antibody, which binds predominantly to cancer cells and then scanning for concentrations of radioactive emissions.^[1]

References

^ "Imaging Techniques for the Diagnosis of Ovarian Cancers: Immunoscintigraphy". 21 December 2004. http://www.medscape.com/viewarticle/494299_6.

This medical article is a stub. You can help Wikipedia by expanding it.

UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

1. 小児の不明熱に対するアプローチ fever of unknown origin in children evaluation

English Journal

Al(18) F labeling of peptides and proteins.

Laverman P1, McBride WJ, Sharkey RM, Goldenberg DM, Boerman OC.
Journal of labelled compounds & radiopharmaceuticals.J Labelled Comp Radiopharm.2014 Apr;57(4):219-23. doi: 10.1002/jlcr.3161. Epub 2014 Jan 10.
Radiolabeled receptor-binding peptides and proteins have emerged as an important class of radiopharmaceuticals that have changed radionuclide imaging in clinical practice. Many strategies have been developed to radiolabel these peptide and proteins with fluorine-18. The majority of these methods is
PMID 24408125

Abundant in vitro expression of the oncofetal ED-B-containing fibronectin translates into selective pharmacodelivery of (131)I-L19SIP in a prostate cancer patient.

Locher R1, Erba PA, Hirsch B, Bombardieri E, Giovannoni L, Neri D, Dürkop H, Menssen HD.
Journal of cancer research and clinical oncology.J Cancer Res Clin Oncol.2014 Jan;140(1):35-43. doi: 10.1007/s00432-013-1538-6. Epub 2013 Oct 17.
PURPOSE: The extradomain B of fibronectin (ED-B) is a promising vascular target for selective pharmacodelivery in cancer patients. We analyzed a large series of prostatectomies from patients with prostate cancer, hyperplastic prostate disease, and normal prostates to study extent and tumor-selectivi
PMID 24132461

The Role of PAM4 in the Management of Pancreatic Cancer: Diagnosis, Radioimmunodetection, and Radioimmunotherapy.

Han S, Jin G, Wang L, Li M, He C, Guo X, Zhu Q.
Journal of immunology research.J Immunol Res.2014;2014:268479. Epub 2014 Apr 10.
PAM4, a new monoclonal antibody (MAb) known as clivatuzumab, is highly reactive with pancreatic cancer and precursor lesions. It is absent from the normal tissues and has limited reactivity with nonpancreatic cancer. The detailed characteristic of the PAM4 epitope is unknown but recent studies have
PMID 24818166